Bayer HealthCare, a Germany Headquarter Chemical Company, is buying Teva Pharmaceuticals, a US-based animal health business, for USD 60 million up front, plus up to USD 85 million in manufacturing and sales milestones. Bayer HealthCare maintains taking on Teva’s the animal health operation will allow the expansion of its companion (pet food) and food animal product lines in the U.S., including the introduction of anti-infective and reproductive hormones. The Teva business will be integrated into Bayer’s own animal health business.
Featured News
Age-Restriction Laws Are Proliferating; So Too Are the Difficult Tradeoffs Policymakers Face
Dec 23, 2025 by
CPI
Federal AI Strategy Raises Compliance Stakes for Banks and Big Tech
Dec 23, 2025 by
CPI
Google Sues Alleged China-Based Hackers Over Widespread Phishing Scheme
Dec 22, 2025 by
CPI
Europe Moves to Clarify What Counts as Personal Data
Dec 22, 2025 by
CPI
Larry Ellison Offers $40 Billion Guarantee as Paramount Renews Bid for Warner Bros
Dec 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi